These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21385322

  • 1. Metabolism of ophthalmic timolol: new aspects of an old drug.
    Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J.
    Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
    [Abstract] [Full Text] [Related]

  • 2. Cardiac safety of ophthalmic timolol.
    Mäenpää J, Pelkonen O.
    Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
    [Abstract] [Full Text] [Related]

  • 3. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
    Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O.
    Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
    [Abstract] [Full Text] [Related]

  • 4. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
    Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M.
    Scand J Clin Lab Invest; 2007 Jul; 67(2):237-45. PubMed ID: 17366003
    [Abstract] [Full Text] [Related]

  • 5. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol.
    Yang Y, Wu K, Yuan H, Yu M.
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):163-71. PubMed ID: 19284319
    [Abstract] [Full Text] [Related]

  • 6. Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat.
    Dumouchel JL, Argikar UA, Spear J, Brown A, Dunne CE, Kramlinger VM, Cirello AL, Gunduz M.
    Drug Metab Lett; 2017 Apr; 11(2):102-110. PubMed ID: 28891437
    [Abstract] [Full Text] [Related]

  • 7. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI, He H, Wood AJ.
    JAMA; 2017 Apr; 274(20):1611-3. PubMed ID: 7474246
    [Abstract] [Full Text] [Related]

  • 8. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study.
    Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J.
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):497-501. PubMed ID: 20925579
    [Abstract] [Full Text] [Related]

  • 9. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
    Mäenpää J, Volotinen-Maja M, Kautiainen H, Neuvonen M, Niemi M, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
    [Abstract] [Full Text] [Related]

  • 10. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
    Tan AY, LeVatte TL, Archibald ML, Tremblay F, Kelly ME, Chauhan BC.
    J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
    [Abstract] [Full Text] [Related]

  • 11. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
    Ishii Y, Nakamura K, Tsutsumi K, Kotegawa T, Nakano S, Nakatsuka K.
    J Clin Pharmacol; 2000 Feb; 40(2):193-9. PubMed ID: 10664926
    [Abstract] [Full Text] [Related]

  • 12. Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma.
    Hegde RR, Bhattacharya SS, Verma A, Ghosh A.
    Curr Eye Res; 2014 Feb; 39(2):155-63. PubMed ID: 24073659
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes.
    Chiang CH, Ho JI, Chen JL.
    J Ocul Pharmacol Ther; 1996 Feb; 12(4):471-80. PubMed ID: 8951683
    [Abstract] [Full Text] [Related]

  • 14. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
    Korte JM, Kaila T, Saari KM.
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
    [Abstract] [Full Text] [Related]

  • 15. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
    Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimäki T, Kähönen M.
    Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y, Nakamura K, Matsuki S, Uemura N, Muraguchi R, Nakagawa M, Nakano S, Nakatsuka K.
    J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
    [Abstract] [Full Text] [Related]

  • 17. Beta-adrenergic glaucoma drugs reduce lymphatic clearance from the eye: A sequential photoacoustic imaging study.
    Hanna J, Yücel YH, Zhou X, Kim N, Irving H, Gupta N.
    Exp Eye Res; 2021 Nov; 212():108775. PubMed ID: 34599970
    [Abstract] [Full Text] [Related]

  • 18. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma.
    Ergin A, Ornek K, Güllü R, Bulcun E, Ekici M, Ekici A.
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):463-6. PubMed ID: 19552600
    [Abstract] [Full Text] [Related]

  • 19. Comparison of ophthalmic beta-blocking agents.
    Lesar TS.
    Clin Pharm; 1987 Jun; 6(6):451-63. PubMed ID: 2891463
    [Abstract] [Full Text] [Related]

  • 20. Effects of topically applied falintolol: a new beta-adrenergic antagonist for treatment of glaucoma.
    Himber J, Sallee VL, Andermann G, Bouzoubaa M, Leclerc G, De Santis L.
    J Ocul Pharmacol; 1987 Jun; 3(2):111-20. PubMed ID: 2903204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.